Sentiss Pharma Private Limited

Delhi Institute of Pharmaceutical Sciences and Research (dipsar)

Delhi Institute of Pharmaceutical Sciences and Research

Promed Exports Private Limited

Deepak Bahri

Mandar V Shah

Manish Kumar Singh

Divya Pandit

Naresh Kumar

Suresh Kumar Gupta

Sushma Srivastava

Ankita Nagpal

Rohit Saxena

Sateesh Kumar Chauhan

Sai Kiran Jana

Shyam Sunder Agrawal

Kishor Deo

Mallinath Harwalkar

Renu Agrawal

Vivekanandan Kalai Selvan

The present invention provides the sterilization of an ophthalmic composition comprising timolol or salt thereof optionally with pharmaceutically acceptable agent(s) wherein the sterilization is achieved through aseptic filtration technique. Further the present invention provides the sterilization process by optimising the process parameters by varying the heating time at a temperature to control the viscosity of the ophthalmic composition of present invention through aseptic filtration technique wherein the filtration is done under aseptic condition through 0.45 μm clarification pre-filter followed by 0.2μ sterilizing grade filter. The process is simple and economical.

Sterilization process of timolol gel forming solution through aseptic filtration

A sterile aqueous formulation of a carbonic anhydrase inhibitor such as brinzolamide in combination with polymers like Soluplus&#xae; and a surfactant like polysorbate 80, as well as methods of preparation thereof, is disclosed. The formulation relates to the highly solubilized or an amorphous form of poorly insoluble drugs/active ingredient(s) to improve its bio-availability and manufacturability.

Pharmaceutical composition comprising brinzolamide

Disclosed herein an ophthalmic formulation comprises carbonic anhydrase inhibitor(s) alone, in an aqueous solution or a combination of two intraocular pressure (IOP) reducing and/or glaucoma treatment agents or a combination of three intraocular pressure (IOP) reducing and/or glaucoma treatment agents and a manufacturing process thereof. The present invention further relates to the composition(s) manufactured by the process described herein and methods for treating persons suffering from glaucoma or ocular hypertension. In particular, the persons are treated with carbonic anhydrase inhibitor(s) alone or a combination of two intraocular pressure (IOP) reducing and/or glaucoma treatment agents or a combination of three intraocular pressure (IOP) reducing and/or glaucoma treatment agents to control their intraocular pressure (IOP). Further disclosed herein the formulations as manufactured relate to a highly solubilized form of poorly insoluble drugs/active ingredient(s) to improve its bio-availability and manufacturability.

Ophthalmic solution

The present invention provides an aqueous ophthalmic composition comprising an alpha-2 adrenergic receptor agonist and a non-ionic cellulosic polymer, the solution having a pH less than 6.5. The present invention also provides an aqueous ophthalmic composition comprising an alpha-2 adrenergic receptor agonist and a benzododecinium halide. Also provided are methods of manufacture, use and method of reducing intraocular pressure in the patient in need thereof.

Topical brimonidine tartrate ophthalmic solution

The present invention provides a process of manufacturing a sterile, ophthalmic pharmaceutical suspension comprising sterile active ingredient(s) such as sterile carbonic anhydrase inhibitors (CAIs) wherein the process does not involve the use of any special equipment's such as ball mill, milling bottle and/or jet mill The present process is simple, cost effective and efficient.

Process for manufacturing sterile ophthalmic pharmaceutical suspensions

The present invention provides an improved novel process of manufacturing a sterile, ophthalmic pharmaceutical suspension comprising an active ingredient(s) such as carbonic anhydrase inhibitors (CAIs) wherein the said process involves solubilization, followed by controlled precipitation of carbonic anhydrase inhibitors of the right particle size, e.g., less than 10 micron, preferably less than 5 micron (D) by varying pH with a little or no homogenization. Said process further does not require the use of any special equipment such as ball mill, milling bottle and/or jet mill. This newly improved process is simple, cost effective and efficient.

The present invention relates to a process for manufacturing an ophthalmic formulation of a carbonic anhydrase inhibitor, hydroxyl ethyl cellulose (HEC), and a beta-adrenergic antagonist for use in the treatment of ocular hypertension and glaucoma wherein the ophthalmic pharmaceutical formulation is devoid of benzalkonium chloride or any other preservatives. The present process for manufacturing is simpler, cost effective process to prepare the pharmaceutical ophthalmic formulation in a single tank, without the use of additional tanks that can be sterile filtered.

Preservative-free ophthalmic pharmaceutical formulation

The present invention relates to a synergistic herbal composition for lowering the intra ocular pressure in different types of glaucoma and process for the preparation of the same in pharmaceutically acceptable dosage forms.

Growing community of inventors

New Delhi, India

Deepak Bahri